Vitamin D3 Supplementation for Heart Failure Patients

NCT ID: NCT01636570

Last Updated: 2017-04-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if treatment with vitamin D3 of 10,000 International Units (IU) daily in vitamin D deficient patients for 6 months will improve B type natriuretic peptide (BNP), a marker of heart function, compared to placebo. The investigators also aim to determine if vitamin D helps cardiopulmonary function as evaluated by cardiopulmonary exercise test (CPX), laboratory values, strength, and quality of life in patients with stable congestive heart failure (Class II or III).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Vitamin D Deficiency Cardiomyopathy Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D3 (cholecalciferol)

10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.

Group Type ACTIVE_COMPARATOR

Vitamin D3 (cholecalciferol)

Intervention Type DRUG

10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.

Sugar Pill

Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.

Group Type PLACEBO_COMPARATOR

Placebo Comparator: Sugar Pill

Intervention Type DRUG

Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo Comparator: Sugar Pill

Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.

Intervention Type DRUG

Vitamin D3 (cholecalciferol)

10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bio-tech Pharmacal Bio-tech Pharmacal

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* NYHA Heart Failure Class II or II, stable
* Vitamin D deficiency (32 ng/ml or less)
* No recent medication changes for 3 months
* Females of childbearing age must use effective contraceptive if they are sexually active

Exclusion Criteria

* Hypercalcemia
* Nephrolithiases
* Sarcoidosis
* Acute cardiac insufficiency
* Pregnancy
* Breastfeeding
* Any clinically unstable medical condition
* Supplements of greater than or equal to 1000 units of vitamin D per day
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Saint Patrick Hospital

OTHER

Sponsor Role collaborator

Heidi Moretti, MS, RD

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Heidi Moretti, MS, RD

Co-Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bradley D Berry, MD

Role: PRINCIPAL_INVESTIGATOR

International Heart Institute of Montana

Heidi D Moretti, MS, RD

Role: STUDY_DIRECTOR

Saint Patrick Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

International Heart Institute of Montana

Missoula, Montana, United States

Site Status

Saint Patrick Hosptial

Missoula, Montana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Moretti HD, Colucci VJ, Berry BD. Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial. BMC Cardiovasc Disord. 2017 Oct 30;17(1):274. doi: 10.1186/s12872-017-0707-y.

Reference Type DERIVED
PMID: 29084522 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VitD3HF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vitamin D and Mortality in Heart Failure
NCT01326650 COMPLETED PHASE4